CA2290021A1 - Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy - Google Patents

Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy Download PDF

Info

Publication number
CA2290021A1
CA2290021A1 CA002290021A CA2290021A CA2290021A1 CA 2290021 A1 CA2290021 A1 CA 2290021A1 CA 002290021 A CA002290021 A CA 002290021A CA 2290021 A CA2290021 A CA 2290021A CA 2290021 A1 CA2290021 A1 CA 2290021A1
Authority
CA
Canada
Prior art keywords
antagonist
antibody
tumor necrosis
necrosis factor
vascular endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290021A
Other languages
English (en)
French (fr)
Inventor
Marc Feldmann
Ravinder Nath Maini
Ewa Maria Paleolog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2290021A1 publication Critical patent/CA2290021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002290021A 1997-05-12 1998-05-12 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy Abandoned CA2290021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85488197A 1997-05-12 1997-05-12
US08/854,881 1997-05-12
PCT/GB1998/001343 WO1998051344A1 (en) 1997-05-12 1998-05-12 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Publications (1)

Publication Number Publication Date
CA2290021A1 true CA2290021A1 (en) 1998-11-19

Family

ID=25319772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290021A Abandoned CA2290021A1 (en) 1997-05-12 1998-05-12 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Country Status (6)

Country Link
EP (2) EP1170017A1 (OSRAM)
JP (1) JP2001525816A (OSRAM)
AU (1) AU7345798A (OSRAM)
CA (1) CA2290021A1 (OSRAM)
HK (1) HK1044887A1 (OSRAM)
WO (1) WO1998051344A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
AU764629B2 (en) 1998-01-22 2003-08-28 Btg International Limited Inhibition of cytokine production
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
AU4541101A (en) * 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US7842691B2 (en) 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
CA2536321A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
US9149809B2 (en) 2011-05-06 2015-10-06 Bio-Rad Laboratories, Inc. Thermal cycler with vapor chamber for rapid temperature changes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736076A1 (en) * 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DK1975181T3 (da) * 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

Also Published As

Publication number Publication date
HK1044887A1 (en) 2002-11-08
EP1170017A1 (en) 2002-01-09
AU7345798A (en) 1998-12-08
EP0980258A1 (en) 2000-02-23
WO1998051344A1 (en) 1998-11-19
JP2001525816A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
EP1170017A1 (en) Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
EP0936923B1 (en) SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
CN111068062B (zh) 治疗白介素-6相关疾病的方法
EP0783893B1 (en) Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
US5888510A (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ES2247635T3 (es) Anticuerpos anti-tnf/receptor de tnf y metotrexato en el tratamiento de enfermedades autoinmunes.
WO2001037874A2 (en) Treatment of psoriasis by using an antibody to tnf alpha
AU2003264629B2 (en) Anti-TNF Antibodies and Methotrexate in the Treatment of Autoimmune Disease
AU2012202134B2 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
HK40019620B (en) Methods for treating interleukin-6 related diseases
HK40019620A (en) Methods for treating interleukin-6 related diseases
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
HK1096859B (en) Methods for treating interleukin-6 related diseases
HK1158078A (en) Methods for treating interleukin-6 related diseases
HK1135027A (en) Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
HK1020011B (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
HK1127497B (en) Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
AU2013202407A1 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead